Twentyeight Health vs Pfizer
Side-by-side comparison of AI visibility scores, market position, and capabilities
Twentyeight Health provides affordable telehealth and mail-order pharmacy for contraception, STI testing, and reproductive health to underserved and low-income women.
About
Twentyeight Health is a reproductive health telehealth company founded in 2019 that focuses specifically on expanding access to contraception and reproductive healthcare for underserved women, including those on Medicaid, without insurance, or in rural areas. The platform provides online consultations with licensed providers for birth control prescriptions, STI testing kits by mail, emergency contraception, and general reproductive health questions at accessible price points with Medicaid acceptance. Twentyeight raised $25M and has enrolled hundreds of thousands of patients, with a focus on the communities most affected by reproductive healthcare access gaps. The company differentiates from other telehealth platforms by prioritizing Medicaid acceptance, multilingual care, and a health equity mission rather than serving primarily the commercially insured population. Twentyeight operates in most US states and has built relationships with state health departments and safety-net healthcare organizations. As access to reproductive healthcare has become more constrained in some US states, Twentyeight's telehealth model has become an increasingly critical access point for patients who cannot easily reach in-person reproductive health services.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
About
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.